Karyopharm: Another 2 Year Wait For Data [Seeking Alpha]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Seeking Alpha
shapecharge/E+ via Getty ImagesI haven't covered Karyopharm Therapeutics Inc. (NASDAQ:KPTIthe last 11 months. I willquoteall those 8 reasons, and then focus on those still relevant:One, the company had earlier said it will submit an NDA in liposarcoma in Q1 2021; however, despite positive data from SEAL, it didn't. Two, XPOVIO's (selinexor) Q4 2020 sales were less than stellar, and QoQ uptake of the drug hasn't progressed by a large percentage. Three, a number of competing drugs have emerged in some of the indications where XPOVIO is approved. Four, the SIENDO trial readout in endometrial cancer, probably the molecule's most high-potential indication, is still two quarters away, and the market isn't keeping focus on SIENDO. Five, the market must still be worried about selinexor's toxicity profile, recalling the nightmarish scenario surrounding its original approval for penta-refractory multiple myeloma, in 2019. Six, insiders hate the stock - they have always sold, and never bought, b
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Florida Cancer Specialists & Research Institute Shares Pharmacy Expertise To Advance Medically Integrated Oncology Care [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor) [Yahoo! Finance]Yahoo! Finance
- Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)Business Wire
- Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 2/29/24 - Miss
KPTI
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- KPTI's page on the SEC website